Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

The latest health briefs reveal Novo Nordisk's promising obesity treatment and a $7.4 billion Purdue Pharma settlement over ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a ...

Robert F. Kennedy, Jr, the nominee for Secretary of HHS, has made promises about the status of his stake in anti-vaccine nonprofits and notable pharma companies as his confirmation hearing approaches.

Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...